Skip to main content

Table 1 Clinical characteristics of Responders and Partial-/Non-Responders at baseline and under treatment with Anti-T2 biological therapy

From: Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study

Variable Baseline Under treatment Mean of difference Percentage change (%) P- Value
Responders (n = 13)
Age (years) 59.4 ± 9.8
Sex (f/m) (9/4)
BMI (kg/m2) 26.4 ± 6.1
Blood eosinophil count (/μL) 620.8 ± 378.8 97.7 ± 160.7 − 523.1 − 84  < 0.01
FEV1(l) 2.1 ± 0.88 2.6 ± 1.1 + 0.520 + 24  < 0.01
FEV% 75.8 ± 21.7% 96.2 ± 18.1% + 20.4% + 26  < 0.01
FEF25–75 (l/s) 1.03 ± 0.77 1.64 ± 1.06 + 0.61 + 59  < 0.01
RV% 153 ± 21% 121 ± 20% − 32% − 21 0.02
RV/TLC 48 ± 9% 38 ± 9% − 10% − 21 0.02
FDR (KPa/l/s) 0.26 ± 0.20 0.12 ± 0.16 − 0.13 − 50  < 0.01
FDR%pred 270% ± 151 168% ± 85 − 103% − 37 0.02
FeNo(ppb) 56.1 ± 26.4 40.8 ± 27.5 − 15.31 − 27  < 0.01
ACT score 14.2 ± 5.3 19.8 ± 4.7 + 5.5 + 39  < 0.01
Number of exacerbations 5.5 ± 3.1 1.1 ± 1.2 − 4.4 − 80  < 0.01
OSC dose (mg) 5.9 ± 5 0.4 ± 0.9 − 5.5 − 93  < 0.01
Partial-/non-responders (n = 7)
Age (years) 60.86 ± 8.30
Sex (f/m) (3/4)
BMI (kg/m2) 29.86 ± 3.0
Blood eosinophil count (/μL) 474.3 ± 420.1 200.0 ± 355.9 − 274.2 − 58  > 0.05
FEV1 (l) 2.0 ± 0.58 1.7 ± 0.41 − 0.343 − 17  > 0.05
FEV% 77.6 ± 22.7% 67.1 ± 20.5% − 10.4% − 13  > 0.05
FEF25–75 (l/s) 1.13 ± 0.72 0.81 ± 0.45 − 0.32 − 28  > 0.05
RV% 140 ± 29% 150 ± 29% + 10% + 7  > 0.05
RV/TLC 45 ± 8% 50 ± 3% + 5% + 11  > 0.05
FDR (KPa/l/s) 0.13 ± 0.11 0.23 ± 0.17 + 0.10 + 76  > 0.05
FDR%pred 146% ± 76% 209% ± 151% + 63% + 43  > 0.05
FeNo (ppb) 41.4 ± 43.7 57.9 ± 38.7 + 16.4 + 39  > 0.05
ACT score 17.9 ± 4.9 17.3 ± 3.6 − 0.571 − 3  > 0.05
Number of exacerbations 4.1 ± 2.9 3.0 ± 2.0 − 1.14 − 27  > 0.05
OSC dose (mg) 7.2 ± 5.1 4.7 ± 3.7 − 2.6 36  > 0.05
  1. Values at baseline and under treatment, as well as means of differences (+ or -) are presented as means ± standard deviations
  2. Absolute blood eosinophils (cells/µl), FEV1: forced expiratory volume in the 1 s (l), FEF25-75: forced expiratory flow between 25 and 75% of the forced vital capacity, RV: residual volume, TLC: total lung capacity, FDR (%): frequency dependence resistance (R5-20 kPa/l/s) and predicted values, FeNO: fractional exhaled nitric oxide (ppb), ACT: asthma control test score, number of exacerbations in the last 12 months, OCS: oral corticosteroid (mg)
  3. P values according to an appropriate test (t. test or Wilcoxon test). P-values in the last column represent test of baseline data vs. data under anti-T2 biological treatment within each of the two groups (responders vs. partial/non-responders). At baseline, clinical variables were also tested between groups and did not show any significant differences, except for FDR%pred (p = 0.038)